CASI Pharmaceuticals, Inc.
CASI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -26.3% | -33.1% | -53.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 23% | 49.3% | 58% | 24.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -328.6% | -262.4% | -169.1% | -73.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -353.9% | -320.4% | -172.3% | -107.6% |
| EPS Diluted | -0.68 | -0.86 | -0.69 | -0.93 |
| % Growth | 20.9% | -24.6% | 25.8% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |